The Food and Drug Administration recently granted Gilead Sciences (NASDAQ:GILD) priority review for its much-awaited hepatitis C drug sofosbuvir. Current treatments are far from perfect for the 3.2 million people suffering from chronic forms of the disease. This novel oral therapy has a lot going for it, which has some analysts thinking it could potentially hit $5 billion in peak sales. In the following video, Fool contributor Maxx Chatsko explains how Gilead's drug raises the bar for the future of hepatitis C treatment.
Fool contributor Maxx Chatsko has no position in any stocks mentioned. Check out his personal portfolio, his CAPS page, or follow him on Twitter @BlacknGoldFool to keep up with his writing on energy, bioprocessing, and biotechnology.
The Motley Fool recommends Gilead Sciences and Vertex Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Is Gilead Sciences, Inc. a Buy in 2018?
Focus on the future rather than the past for this big biotech.
2017 Was a Year to Forget for Gilead Sciences, Inc., but This Year Could Be Better
In the short term, the biotech's success is still tied to its HIV and HCV franchises, but keep an eye on the pipeline.
5 Ways Gilead Sciences Plans to Return to Growth
Gilead's CEO reveals the biotech's game plan at the J.P. Morgan Healthcare Conference.